Compare DexCom, Inc. (DXCM) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kimberly Clark Corp — how do they compare? DexCom, Inc. trades at $89.04 (market cap $33.79B), while Kimberly Clark Corp trades at $108.4 (market cap $36.11B). The key difference: DexCom, Inc. and Kimberly Clark Corp are close in size by market cap, and Kimberly Clark Corp pays a 4.72% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KMB | |
|---|---|---|
Market Cap | $33.79B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $134.81 |
52-Week Low | $54.84 | $93.05 |
Enterprise Value | $33.24B | $41.67B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Kimberly-Clark (KMB) trades at $108.02, down 1.51% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings missed expectations, prompting a lowered 2026 outlook due to China diaper market weakness and North American volatility. The company maintains strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, but faces revenue pressure with 2025 sales at $16.45B, down from prior years. Dividend payments remain steady at $1.28 per share, supporting income investors.
KMB presents a cautious outlook with near-term headwinds overshadowing long-term strengths. Investment opportunities include a discounted valuation relative to historical levels and a reliable dividend yield. Key risks involve execution challenges in China, competitive pressures, and macroeconomic sensitivity. Analyst consensus is mixed, with a $113.20 price target suggesting modest upside, but investors should weigh operational uncertainties against the company's brand resilience and cost-saving initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
